✓ Translated by DotMD AI Clinical Council Source: Clinical science (London, England : 1979) • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #25849646 ↗

Randomized Controlled Trial: Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus (N = 28)

Original Paper Title: “Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 28
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Salt supplementation significantly reduced the MAP lowering effects of telmisartan (P<0.05). The present study demonstrates that salt supplementation blunts the telmisartan induced increase in PRA in patients with type 2 diabetes.
  • Study Design & Sample: Randomized Controlled Trial published in Clinical science (London, England : 1979) (N = 28 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical science (London, England : 1979) (2015), this randomized controlled trial evaluating 28 human participants investigated: Current guidelines recommend low dietary salt intake (LDS) in patients with diabetes to reduce blood pressure (BP). Key clinical takeaway: Salt supplementation significantly reduced the MAP lowering effects of telmisartan (P<0.05). The present study demonstrates that salt supplementation blunts the telmisartan induced increase in PRA in patients with type 2 diabetes.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical science (London, England : 1979), 2015-09-15; N = 28; Rigor 88/100): Salt supplementation significantly reduced the MAP lowering effects of telmisartan (P<0.05). The present study demonstrates that salt supplementation blunts the telmisartan induced increase in PRA in patients with type 2 diabetes.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: telmisartan → Rx: angiotensin-ii → Rx: pressure-pain-and-mucus-acetaminophen-guaifenesin-phenylephrine-hcl → Rx: sinus-pressure-plus-pain-pe-acetaminophen-and-phenylephrine → Condition: diabetes → Condition: type-1-diabetes-mellitus-with-ketoacidosis-without-coma → Condition: type-1-diabetes-mellitus-with-ketoacidosis-with-coma →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 25849646: Randomized Controlled Trial: Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus (N = 28)

3 of 3 Free Questions Remaining